Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) (INTEREST)
A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human IFN Beta-1a) and Placebo in the Treatment of Patients With Moderate or Severe Acute Respiratory Distress Syndrome
Sponsor: Faron Pharmaceuticals Ltd
Terminated
Day 90 results indicate IMP did not reduce mortality or ventilator free days
Other terminated trials from Faron Pharmaceuticals Ltd
More terminations from Faron Pharmaceuticals Ltd
Other Respiratory Distress Syndrome, Adult trials with similar outcome
A PHASE3 clinical study on Respiratory Distress Syndrome, Adult, this trial is terminated or withdrawn. The trial is conducted by Faron Pharmaceuticals Ltd and has accumulated 13 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 8 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2019 — Apr 2020 [monthly]
Terminated PHASE3
-
Jul 2018 — Jan 2019 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Jul 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jul 2017 [monthly]
Recruiting PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Faron Pharmaceuticals Ltd
- Seventh Framework Programme
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Augsburg, Germany , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Bonn, Germany , Brest, France , Bristol, United Kingdom , Brussels, Belgium , Cardiff, United Kingdom and 48 more locations